.

BioPharmaceutical Business Intelligence

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Merck
Fuji
Boehringer Ingelheim
Novartis
Federal Trade Commission
Cantor Fitzgerald
Cerilliant
Medtronic
Chubb
QuintilesIMS

Generated: September 19, 2017

DrugPatentWatch Database Preview

MEGACE ES Drug Profile

« Back to Dashboard

Which patents cover Megace Es, and when can generic versions of Megace Es launch?

Megace Es is a drug marketed by Endo Pharms Inc and is included in one NDA. There are six patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and eighty-six patent family members in twenty-seven countries.

The generic ingredient in MEGACE ES is megestrol acetate. There are eighteen drug master file entries for this compound. Twenty-seven suppliers are listed for this compound. Additional details are available on the megestrol acetate profile page.

Summary for Tradename: MEGACE ES

Patents:6
Applicants:1
NDAs:1
Suppliers / Packagers: see list6
Bulk Api Vendors: see list56
Clinical Trials: see list21
Patent Applications: see list7,167
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:MEGACE ES at DailyMed

Pharmacology for Tradename: MEGACE ES

Ingredient-typeProgesterone Congeners
Drug ClassProgestin
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Endo Pharms Inc
MEGACE ES
megestrol acetate
SUSPENSION;ORAL021778-001Jul 5, 2005ABRXYesYes► Subscribe► SubscribeY ► Subscribe
Endo Pharms Inc
MEGACE ES
megestrol acetate
SUSPENSION;ORAL021778-001Jul 5, 2005ABRXYesYes► Subscribe► Subscribe ► Subscribe
Endo Pharms Inc
MEGACE ES
megestrol acetate
SUSPENSION;ORAL021778-001Jul 5, 2005ABRXYesYes► Subscribe► Subscribe ► Subscribe
Endo Pharms Inc
MEGACE ES
megestrol acetate
SUSPENSION;ORAL021778-001Jul 5, 2005ABRXYesYes► Subscribe► Subscribe ► Subscribe
Endo Pharms Inc
MEGACE ES
megestrol acetate
SUSPENSION;ORAL021778-001Jul 5, 2005ABRXYesYes► Subscribe► Subscribe ► Subscribe
Endo Pharms Inc
MEGACE ES
megestrol acetate
SUSPENSION;ORAL021778-001Jul 5, 2005ABRXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: MEGACE ES

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Endo Pharms Inc
MEGACE ES
megestrol acetate
SUSPENSION;ORAL021778-001Jul 5, 2005► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: MEGACE ES

Drugname Dosage Strength RLD Submissiondate
megestrol acetateOral Suspension125 mg/mLMegace ES

Non-Orange Book Patents for Tradename: MEGACE ES

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,459,283Nanoparticulate compositions having lysozyme as a surface stabilizer► Subscribe
8,124,057Propellant-based nanoparticulate dry powder aerosols and method of making► Subscribe
7,521,068Dry powder aerosols of nanoparticulate drugs► Subscribe
7,931,917Nanoparticulate fibrate formulations► Subscribe
6,316,029 Rapidly disintegrating solid oral dosage form► Subscribe
6,969,529 Nanoparticulate compositions comprising copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers► Subscribe
8,652,464Method of treatment using nanoparticulate compositions having lysozyme as a surface stabilizer► Subscribe
8,236,352Glipizide compositions► Subscribe
8,309,136In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate or nanoparticulate active agent compositions► Subscribe
6,811,767 Liquid droplet aerosols of nanoparticulate drugs► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: MEGACE ES

Country Document Number Estimated Expiration
European Patent Office1901713► Subscribe
Austria464880► Subscribe
Israel188322► Subscribe
Japan2011516421► Subscribe
European Patent Office1282399► Subscribe
Denmark1471887► Subscribe
Australia2003261167► Subscribe
TaiwanI347198► Subscribe
Japan2010013462► Subscribe
Eurasian Patent Organization200401556► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Julphar
Johnson and Johnson
McKinsey
Deloitte
Novartis
Chinese Patent Office
UBS
Express Scripts
AstraZeneca
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot